High Lipoprotein(a) / Lp(a): What It Means, Cardiovascular Risk and What to Do

High lipoprotein(a) is an inherited cardiovascular risk factor: you can have apparently normal cholesterol and still carry a silent risk that a basic lipid panel does not show.

The usual abbreviation is Lp(a). It is not just “another cholesterol number.” It is an LDL-like particle with one ApoB molecule, attached to an additional protein called apolipoprotein(a). That extra component changes how the particle behaves: it is more atherogenic, more inflammatory and, in selected contexts, more linked to clotting biology and aortic valve stenosis.

The difficult part is that Lp(a) is mostly inherited. Diet, fasting, running more or taking supplements may improve your overall cardiovascular risk, but they usually do not lower Lp(a) very much. That is not a reason to give up. It is a reason to interpret the result properly and decide how intensive the rest of your plan should be: LDL-C, ApoB, blood pressure, glucose, insulin, inflammation, visceral fat, sleep, exercise and medical follow-up.

At Progevita, we treat Lp(a) as a marker of residual risk. The goal is not to frighten you with one number. The goal is to use that number to design more precise cardiovascular prevention.

Evidence review note: this article was updated in May 2026 against EAS 2022, NLA 2024, SEA 2024, AHA and PubMed literature. It is educational content; clinical decisions depend on your history, examination, medication, vascular imaging and medical judgement.

What is lipoprotein(a), or Lp(a)?

Lp(a) is a lipoprotein produced mainly in the liver. Structurally, it resembles an LDL particle: it carries cholesterol and contains one apolipoprotein B100 molecule, the protein that identifies atherogenic particles. The difference is that Lp(a) also carries apolipoprotein(a), encoded by the LPA gene.

Apolipoprotein(a) varies in size from person to person. That is why Lp(a) results may be reported in different units — mg/dL or nmol/L — and why there is no reliable universal conversion between the two. When you receive a result, always check the unit and the lab reference range.

A 2024 review in The Lancet (Nordestgaard et al., PMID: 39278229) puts the issue plainly: around one in five people are at high risk of atherosclerotic cardiovascular disease and aortic valve stenosis because of elevated Lp(a). The American Heart Association gives a similar public-health framing and often uses 125 nmol/L or 50 mg/dL as a level associated with increased risk, with clinical interpretation.

What high lipoprotein(a) means

High Lp(a) does not mean you are destined to have a heart attack. It means your baseline risk may be underestimated if you only look at total cholesterol, LDL-C and HDL-C. Lp(a) can contribute to three relevant processes:

• Atherosclerosis: plaque formation and progression in arteries.
• Vascular inflammation: more irritation inside the arterial wall, especially when other markers such as hsCRP are also elevated.
• Calcific aortic valve stenosis: progressive narrowing of the aortic valve.

The evidence is not based only on weak associations. A 2009 JAMA analysis of 126,634 participants from 36 prospective studies (Emerging Risk Factors Collaboration, PMID: 19622820) found continuous, independent associations between Lp(a), coronary heart disease and ischemic stroke. The same year, a genetic study in the New England Journal of Medicine (Clarke et al., PMID: 20032323) showed that variants at the LPA locus raised Lp(a) and increased coronary disease risk, supporting a causal role.

The European Atherosclerosis Society updated its position in 2022: elevated Lp(a) is a causal factor for atherosclerotic cardiovascular disease and aortic stenosis. The 2024 National Lipid Association focused update (PMID: 38565461) now supports measuring Lp(a) at least once in every adult for risk stratification and recommends cascade screening in first-degree relatives when Lp(a) is elevated.

The Spanish Society of Arteriosclerosis published its own clinical consensus in 2024 (PMID: 38599943) and stressed a practical point: Lp(a) concentration is more than 80% genetically determined and, unlike many cardiovascular risk factors, it is usually not regulated by lifestyle changes.

Normal, high and very high Lp(a) levels

There is no perfect single cut-off. Risk rises gradually, and laboratory methods differ. Still, these ranges are useful for orientation:

Approximate result	mg/dL	nmol/L	Practical interpretation
Low	< 30	< 75	Lp(a) usually adds little to estimated risk.
Intermediate	30-50	75-125	Interpret with family history, ApoB, blood pressure and other factors.
High	> 50	> 125	Additional risk; prevention should be more precise.
Very high	> 100	Often > 250	Needs individual medical assessment and possible family screening.

Two warnings matter. First, do not convert mg/dL to nmol/L by multiplying by a fixed number. Particle size varies between people. Second, a “high” value means different things in a 38-year-old non-smoker with low ApoB and no plaque than in a 58-year-old with hypertension, family history and a high coronary calcium score.

Lp(a), LDL-C, ApoB and no-HDL-C: how they differ

The confusion comes from using the word “cholesterol” for different things. LDL-C measures content. ApoB measures particle number. Lp(a) identifies a specific inherited particle. No-HDL-C groups all atherogenic cholesterol. They are related, but not the same.

Marker	What it measures	Question it answers	Main limitation
LDL-C	Cholesterol carried by LDL	How much cholesterol is inside LDL?	Does not count particles; can underestimate risk in discordance.
ApoB	Number of atherogenic particles	How many “vehicles” are entering the artery wall?	Does not show how much of that risk comes from Lp(a).
Lp(a)	LDL-like particle with ApoB + apolipoprotein(a)	Is there inherited added risk?	Mostly genetic; limited lifestyle response.
No-HDL-C	Total cholesterol minus HDL	How much atherogenic cholesterol is circulating?	Less precise than ApoB when many particles are small.

For the wider measurement map, this guide to longevity biomarkers explains why one number is rarely enough for good decisions.

When Lp(a) should be measured

Lp(a) is usually not included in a basic lipid panel. It has to be requested. Many recent guidance documents support at least one adult measurement, especially when family history or advanced prevention is relevant. Testing makes sense in these situations:

• Premature heart attack, stroke or cardiovascular disease in first-degree relatives.
• Familial hypercholesterolaemia or suspicion of it.
• Early cardiovascular disease not explained by standard risk factors.
• Aortic stenosis, especially earlier than expected.
• “Normal” LDL-C but family history or vascular imaging that does not fit.
• Personalized prevention for people who want to know real risk, not only basic cholesterol.

The AHA recommends that every adult has Lp(a) measured at least once, with particular relevance in people with premature cardiovascular disease, familial hypercholesterolaemia or known high Lp(a) in the family. In close relatives, cascade screening can prevent years of uncertainty.

There are interpretation nuances. Average levels vary by ancestry — they tend to be higher in people of African ancestry — and certain life stages or conditions can affect interpretation: pregnancy, menopause, kidney disease, liver disorders, hypothyroidism or marked inflammation. If a result does not fit the clinical picture, confirm the units, assay and clinical context at the time of testing.

Symptoms of high Lp(a): why risk is usually silent

High Lp(a) usually does not hurt, cause fatigue or create a recognizable signal. That is the problem. Symptoms, if they appear, are symptoms of possible consequences: chest pain from angina, heart attack, stroke, peripheral artery disease or aortic stenosis causing breathlessness, dizziness or fainting.

So the answer to “high Lp(a) symptoms” is short: do not wait for symptoms. Test when your context justifies it. And if your result is high, do not treat it as a sentence; integrate it into a complete cardiovascular assessment.

Can Lp(a) be lowered? What works and what does not

The honest answer is not glamorous: today there is no standard pill or supplement that lowers Lp(a) powerfully, safely and routinely for everyone, with proven cardiovascular outcome reduction as routine care. Lifestyle is essential for lowering overall cardiovascular risk, but it usually does not move Lp(a) much because the marker is mainly genetic.

That does not make habits useless. Quite the opposite. If your Lp(a) is high, the rest of the terrain should be excellent. Fewer atherogenic particles, less mechanical pressure on the artery, lower inflammation, better insulin sensitivity, higher cardiorespiratory fitness and less visceral fat. That is the actionable part.

Option	Effect on Lp(a)	How to interpret it
Statins	May slightly increase it or keep it stable	Not used to lower Lp(a), but still useful when LDL/ApoB and global risk need reduction.
Niacin	Can lower it	Not recommended as a routine strategy because outcome benefit is unclear and adverse effects matter.
PCSK9 inhibitors	Moderate reduction in some patients	May be used in secondary prevention or high-risk settings according to LDL/ApoB and clinician judgement; not a universal Lp(a) indication.
Lipoprotein apheresis	Large but temporary reduction	Reserved for highly selected high-risk cases, often with familial hypercholesterolaemia and documented vascular disease.
Pelacarsen, olpasiran, lepodisiran and others	Large reductions in trials	Promising, but outcome trials still need to prove final clinical benefit.

In FOURIER, O'Donoghue et al. (2019, PMID: 30586750) studied 25,096 patients with established cardiovascular disease and evaluated Lp(a), evolocumab and risk. The NLA 2024 update also notes that lipoprotein apheresis has a U.S. approved indication in very high-risk patients with familial hypercholesterolaemia, documented coronary or peripheral artery disease, persistent Lp(a) ≥60 mg/dL and LDL-C ≥100 mg/dL despite maximally tolerated therapy. That is a narrow scenario, not a general solution.

The fastest-moving area is research. Lepodisiran produced dose-dependent Lp(a) reductions in a 2025 phase 2 trial in NEJM (PMID: 40162643). Olpasiran reduced ApoB-linked oxidized phospholipids in OCEAN(a)-DOSE (PMID: 39937508). Lp(a)HORIZON is testing whether pelacarsen lowers major events in patients with cardiovascular disease and elevated Lp(a) (PMID: 40185318). The key point: lowering the number is not enough; we need fewer heart attacks, strokes and clinical events.

What to do if your Lp(a) is high

The useful question is not “how do I lower this number tomorrow?” It is “what decisions does this result change?” This checklist can guide the conversation with your clinician:

1. Confirm unit and method: mg/dL and nmol/L are not interchangeable through a simple rule. Keep the original report.
2. Review family history: heart attack, stroke, angioplasty, sudden death or early aortic stenosis.
3. Measure ApoB, LDL-C and no-HDL-C: with high Lp(a), reducing other atherogenic particles often becomes more relevant.
4. Assess blood pressure: ideally through repeated measurements or ambulatory monitoring when needed.
5. Check metabolism: HbA1c, glucose, insulin, triglycerides, waist and body composition.
6. Check inflammation: hsCRP, and in a longevity setting, suPAR when available.
7. Consider imaging when appropriate: coronary calcium scoring, carotid ultrasound or other tests depending on age, symptoms and medical judgement.
8. Build follow-up: knowing the number is not enough; you need targets, timing and a plan for repeat biomarkers.

Quick matrix: what changes by context

Scenario	Practical reading	Reasonable clinical discussion
High Lp(a) + low ApoB + no known plaque	Inherited risk, but atherogenic terrain is controlled.	Keep ApoB/LDL low, review blood pressure and habits, decide whether imaging adds value based on age and family history.
High Lp(a) + high ApoB/LDL	Two signals point in the same direction.	More intensive lipid targets, adherence, nutrition, exercise and possible medication depending on global risk.
High Lp(a) + CAC/plaque or premature family history	The marker already coexists with evidence of susceptibility or disease.	More aggressive prevention, imaging/follow-up, family screening and specialist discussion.

This is the logic of preventive medicine: detect risk before it becomes disease. It also connects with inflammaging, because chronic low-grade inflammation can change how cardiovascular markers behave.

How Progevita interprets Lp(a)

At Progevita, we do not use Lp(a) to label someone as “high risk” and stop there. We integrate it into a map that includes biomarkers, physical function and medical context. In a preventive cardiovascular assessment, relevant inputs may include blood pressure, ApoB, full lipid profile, HbA1c, insulin, hsCRP, suPAR, body composition, VO₂max, strength, sleep, stress, family history and, when appropriate, vascular imaging.

The setting matters too. At Balneario de Cofrentes, one hour from Valencia, Progevita combines medical assessment, nutrition, training, sleep, heat exposure, cold exposure and follow-up. It is not a loose lab panel. It is a 12-month plan to reduce measurable risk and improve healthspan. In people with high Lp(a), that usually means more precise management of residual risk.

An anti-inflammatory nutrition plan does not “cure” Lp(a), but it can improve the cardiometabolic terrain: visceral fat, glucose, triglycerides, blood pressure and inflammation. That distinction matters. We do not promise to move what is mostly genetic; we work on what changes outcomes.

Frequently asked questions

What does high lipoprotein(a) mean?

It means you have an elevated amount of Lp(a), an LDL-like particle that carries apolipoprotein(a). High Lp(a) is associated with higher risk of atherosclerotic cardiovascular disease and aortic valve stenosis. It is not a diagnosis on its own, but it changes risk assessment.

Does high Lp(a) cause symptoms?

Usually no. High Lp(a) is silent. Symptoms, if they occur, are symptoms of cardiovascular disease that Lp(a) can contribute to, such as angina, heart attack, stroke or aortic stenosis.

What is a normal Lp(a) level?

It depends on the lab and units. Many guidance documents use below 30 mg/dL or 75 nmol/L as lower risk, and above 50 mg/dL or 125 nmol/L as increased risk. There is no universal conversion between mg/dL and nmol/L.

How often should Lp(a) be tested?

For most adults, once is enough because Lp(a) is largely genetic and stable. Retesting may make sense if the initial result is unclear, units need confirmation, or clinical conditions change.

Can I have high Lp(a) with normal cholesterol?

Yes. LDL-C and total cholesterol can look acceptable while Lp(a) is high. That is why Lp(a) can reveal inherited risk that a basic lipid panel misses.

How can lipoprotein(a) be lowered?

Lifestyle rarely lowers Lp(a) by much, but it reduces overall cardiovascular risk. Current management focuses on LDL/ApoB, blood pressure, glucose, inflammation, smoking, visceral fat, exercise and medical follow-up. Specific Lp(a)-lowering drugs are being tested, but they are not routine treatment yet.

Are Lp(a) and ApoB the same?

No. ApoB estimates the total number of atherogenic particles. Lp(a) is a specific inherited particle that contains ApoB plus apolipoprotein(a). Both can matter, but they answer different questions.

Is high Lp(a) inherited?

Yes. Lp(a) concentration is mainly determined by variants in the LPA gene. If someone has high Lp(a) or premature cardiovascular disease, first-degree relatives may benefit from testing.

References

1. Kronenberg F, Mora S, Stroes ESG, et al. “Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.” European Heart Journal. 2022;43(39):3925-3946. DOI: 10.1093/eurheartj/ehac361.
2. Kronenberg F, Mora S, Stroes ESG, et al. “Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.” Atherosclerosis. 2023;374:107-120. PMID: 37188555.
3. Bajaj A, Boffa MB, Dixon DL, et al. “A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.” Journal of Clinical Lipidology. 2024;18(3):e308-e319. PMID: 38565461.
4. Delgado-Lista J, Mostaza JM, Arrobas-Velilla T, et al. “Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis.” Clínica e Investigación en Arteriosclerosis. 2024;36(4):243-266. PMID: 38599943.
5. Nordestgaard BG, et al. “Lipoprotein(a) and cardiovascular disease.” The Lancet. 2024;404(10459):1255-1264. PMID: 39278229.
6. Emerging Risk Factors Collaboration. “Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.” JAMA. 2009;302(4):412-423. PMID: 19622820.
7. Clarke R, Peden JF, Hopewell JC, et al. “Genetic variants associated with Lp(a) lipoprotein level and coronary disease.” New England Journal of Medicine. 2009;361(26):2518-2528. PMID: 20032323.
8. O'Donoghue ML, Fazio S, Giugliano RP, et al. “Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.” Circulation. 2019;139(12):1483-1492. PMID: 30586750.
9. Nissen SE, et al. “Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).” New England Journal of Medicine. 2025. PMID: 40162643.
10. Cho L, et al. “Design and Rationale of Lp(a)HORIZON Trial.” American Heart Journal. 2025. PMID: 40185318.
11. Rosenson RS, et al. “Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers.” JAMA Cardiology. 2025. PMID: 39937508.
12. Lee SH, et al. “The Emerging Lipid Risk: Lipoprotein(a).” Korean Circulation Journal. 2026. PMID: 41371918.
13. American Heart Association. “Lipoprotein(a).” Patient guidance.
14. MedlinePlus. “Lipoprotein(a) blood test.” U.S. National Library of Medicine.

This article is educational and does not replace individual medical assessment. Lp(a) interpretation depends on age, family history, other biomarkers, medication, cardiovascular imaging and clinical judgement.

Want to understand your real cardiovascular risk beyond a basic cholesterol panel? At Progevita we integrate Lp(a), ApoB and other biomarkers into a personalized preventive assessment. Request an orientation call.